Skip to main content
. 2009 Nov;128(3):420–428. doi: 10.1111/j.1365-2567.2009.03127.x

Figure 1.

Figure 1

Increased survival in tumour-bearing mice treated with transporter associated with antigen processing 1 (TAP1)- and B7.1-expressing tumour cells. C57BL/6 mice were inoculated with live CMT.64 cells (1 × 105 cells per mouse). Three and six days after live tumour cell inoculation, mice (n = 10 in each group) were treated intraperitoneally (i.p.) with γ-irradiated CMT.TAP1/pEF4 tumour cells (1 × 107 cells per mouse) that had been infected either with 1 : 1 [multiplicity of infection (MOI)] vaccinia virus (VV)-B7.1 and VV-Kb or with 1 : 1 (MOI) VV-GFP, and the time of morbidity was recorded. Mice treated with γ-irradiated CMT.64/pp1 cells infected with 1 : 1 (MOI) VV-GFP were used as a negative control (P < 0·05 for mice immunized with CMT.TAP1/pEF4 cells infected with VV-B7.1 compared with mice immunized with CMT.TAP1/pEF4 cells infected with VV-GFP; P < 0·05 for mice immunized with CMT.TAP1/pEF4 cells infected with VV-GFP compared with mice immunized with CMT.64/pp1 cells infected with VV-GFP).